- Aprea Therapeutics press release (NASDAQ:APRE): Q2 EPS of -$4.34 may not be comparable to consensus of -$0.31.
- As of June 30, 2022, the Company had $39.1 million of cash and cash equivalents compared to $53.1 million of cash and cash equivalents as of December 31, 2021. The Company believes its cash and cash equivalents as of June 30, 2022 will be sufficient to meet its current projected operating requirements through the end of 2023.
Aprea TherapeuticsEPS of -$4.34
Recommended For You
More Trending News
About APRE Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| APRE | - | - |
| Aprea Therapeutics, Inc. | ||